Experience with proprotein convertase subtilisin/kexine type 9 inhibitors (PCSK9i) in patients undergoing lipoprotein apheresis.

CONCLUSIONS: 3/4 of LA patients could not stop extracorporeal treatment after PCSK9i administration. In hypercholesterolemic patients with coexisting elevated Lp(a) and progressive cardiovascular disease the combination of LA and PCSK9i could be beneficial. The total patients' number in LA units increases due to persons with Lp(a)-hyperlipoproteinemia. PMID: 31818448 [PubMed - in process]
Source: Atherosclerosis Supplements - Category: Cardiology Authors: Tags: Atheroscler Suppl Source Type: research